Ipilimumab-induced acute generalized exanthematous pustulosis in a patient with metastatic melanoma

Melanoma Research

Volumn 26, Issue 4, 2016, Pages 417-420

  Hwang, Shelley J E ^a,b   Carlos, Giuliana ^a,b   Wakade, Deepal ^a,b   Sharma, Raghwa ^a,c   Fernandez Penas, Pablo ^a,b  

^a WESTMEAD HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF WESTERN SYDNEY   (Australia)

Author keywords

acute generalized exanthematous pustulosis; anti cytotoxic T lymphocyte antigen 4; cutaneous adverse event; immunotherapy; ipilimumab; metastatic melanoma

Indexed keywords

ANTIHISTAMINIC AGENT; EMOLLIENT AGENT; IPILIMUMAB; PEMBROLIZUMAB; PREDNISONE; STEROID; IMMUNOLOGICAL ANTINEOPLASTIC AGENT;

ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; ADULT; ARTICLE; BACK; BODY SURFACE; CANCER CHEMOTHERAPY; CANCER PATIENT; CASE REPORT; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; EOSINOPHIL; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INGUINAL REGION; LOWER LIMB; MALE; METASTATIC MELANOMA; MIDDLE AGED; NEUTROPHIL; PRIORITY JOURNAL; PRURITUS; SKIN BIOPSY; TREATMENT DURATION; TRUNK; UPPER LIMB; MELANOMA; PATHOLOGY; SKIN TUMOR;

ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; HUMANS; IPILIMUMAB; MALE; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS;

EID: 84962054931     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0000000000000261     Document Type: Article

References (20)

1. Barker CA, Postow MA, Khan SA, Beal K, Parhar PK, Yamada Y, et al. Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma. Cancer Immunol Res 2013; 1:92-98.
2. Lacouture ME, Wolchok JD, Yosipovitch G, Kähler KC, Busam KJ, Hauschild A. Ipilimumab in patients with cancer and the management of dermatologic adverse events. J Am Acad Dermatol 2014; 71:161-169.
3. Simeone E, Gentilcore G, Giannarelli D, Grimaldi AM, Caracò C, Curvietto M, et al. Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. Cancer Immunol Immunother 2014; 63:675-683.
4. O'Day SJ, Maio M, Chiarion-Sileni V, Gajewski TF, Pehamberger H, Bondarenko IN, et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol 2010; 21:1712-1717.
5. Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010; 11:155-164.
6. Kyllo RL, Parker MK, Rosman I, Musiek AC. Ipilimumab-associated Sweet syndrome in a patient with high-risk melanoma. J Am Acad Dermatol 2014; 70:e85-e86.
7. Belda Junior W, Ferolla AC. Acute generalized exanthematous pustulosis (AGEP). Case report. Rev Inst Med Trop Sao Paulo 2005; 47:171-176.
8. Chaabane A, Aouam K, Gassab L, Njim L, Boughattas NA. Acute generalized exanthematous pustulosis (AGEP) induced by cefotaxime. Fundam Clin Pharmacol 2010; 24:429-432.
9. Fernando SL. Acute generalised exanthematous pustulosis. Australas J Dermatol 2012; 53:87-92.
10. Goeschke B, Braathen LR. Acute generalized exanthematic pustulosis: a case and an overview of side effects affecting the skin caused by celecoxib and other COX-2 inhibitors reported so far. Dermatology 2004; 209:53-56.
11. Peermohamed S, Haber RM. Acute generalized exanthematous pustulosis simulating toxic epidermal necrolysis: a case report and review of the literature. Arch Dermatol 2011; 147:697-701.
12. Schwarz M, Kreuzer KA, Baskaynak G, Dörken B, le Coutre P. Imatinib-induced acute generalized exanthematous pustulosis (AGEP) in two patients with chronic myeloid leukemia. Eur J Haematol 2002; 69:254-256.
13. Pintova S, Sidhu H, Friedlander PA, Holcombe RF. Sweet's syndrome in a patient with metastatic melanoma after ipilimumab therapy. Melanoma Res 2013; 23:498-501.
14. Berman D, Parker SM, Siegel J, Chasalow SD, Weber J, Galbraith S, et al. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun 2010; 10:11.
15. Tarhini A. Immune-mediated adverse events associated with ipilimumab CTLA-4 blockade therapy: the underlying mechanisms and clinical management. Scientifica (Cairo) 2013; 2013:857519.
16. Sznol MCM, Yuan J, Wolchok J. Key issues in the management of gastrointestinal immune-related adverse events associated with ipilimumab administration. Community Oncol 2013; 10:351-358.
17. Lord JD, Hackman RC, Moklebust A, Thompson JA, Higano CS, Chielens D, et al. Refractory colitis following anti-CTLA4 antibody therapy: analysis of mucosal FOXP3 + T cells. Dig Dis Sci 2010; 55:1396-1405.
18. Kaufman HL, Wolchok JD. Is tumor immunity the same thing as autoimmunity? Implications for cancer immunotherapy. J Clin Oncol 2006; 24:2230-2232.
19. Minkis K, Garden BC, Wu S, Pulitzer MP, Lacouture ME. The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis. J Am Acad Dermatol 2013; 69:e121-e128.
20. Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012; 30:2691-2697.